For research use only. Not for therapeutic Use.
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3].
IMM-H007 inhibits fatty acid import into hepatocytes and liver lipogenesis, and concomitantly stimulates fatty acid oxidation, autophagy, and export of hepatic lipids[2].
IMM-H007 (200 mg/kg, Orally, once per day for 10 days) inhibits ISO-induced cardiac fibrosis and diastolic dysfunction independently of AMPKα2 expression, reduces ISO-induced Smad2/3 phosphorylation downstream of TGFβ1 and cardiac fibrosis via an AMPKα2-independent pathway, but the inhibition of TGFβ1 expression is AMPKα2-dependent[3].
| Catalog Number | I029271 |
| CAS Number | 1221412-23-2 |
| Synonyms | [(2R,3R,4R,5R)-3,4-diacetyloxy-5-[6-(3-hydroxyanilino)purin-9-yl]oxolan-2-yl]methyl acetate |
| Molecular Formula | C22H23N5O8 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H23N5O8/c1-11(28)32-8-16-18(33-12(2)29)19(34-13(3)30)22(35-16)27-10-25-17-20(23-9-24-21(17)27)26-14-5-4-6-15(31)7-14/h4-7,9-10,16,18-19,22,31H,8H2,1-3H3,(H,23,24,26)/t16-,18-,19-,22-/m1/s1 |
| InChIKey | IUDLPZTURGVXEA-WGQQHEPDSA-N |
| SMILES | CC(=O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)NC4=CC(=CC=C4)O)OC(=O)C)OC(=O)C |
| Reference | [1]. Yu J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732. [2]. Shi H, et al. IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet. FEBS Open Bio. 2017 Aug 29;7(9):1379-1391. [3]. Wang SX, et al. IMM-H007 attenuates isoprenaline-induced cardiac fibrosis through targeting TGFβ1 signaling pathway. Acta Pharmacol Sin. 2022 Mar 30. |
